viewWi-LAN Inc

Court says Apple's products do not infringe on Wi-Lan's 4G wireless patents


Wi-LAN (TSE:WIN) (NASDAQ:WILN) shares tanked on Thursday after the company lost out in a patent infringement case against Apple (NASDAQ:AAPL) relating to its LTE, or 4G wireless, patents.

Shares of Wi-LAN were down almost 12 percent at C$3.46 in Toronto. 

Wi-LAN, which makes money through patent lawsuits, started litigation against Apple, HTC Corp and Sierra Wireless in December 2012, claiming infringement of its LTE-related technologies. 

The Canadian owner of patents for technology used in mobile phones has to date signed license and settlement agreements with both HTC and Sierra Wireless to resolve the case. 

But the suit against remaining defendant Apple is being tried in the US District Court for the Southern District of California, and earlier this year, Wi-LAN moved for summary judgement on invalidity claims while Apple moved for summary judgement on both invalidity and non-infringement defenses. 

Wi-LAN, in its update late Wednesday, said judge Dana M. Sabraw issued a ruling in favour of Apple, granting the giant tech company's motion for summary judgement. 

The intellectual property licensing firm is currently reviewing the ruling, it said, with the case remaining before the courts. The company also has an additional suit in the same district involving Apple, related to the infringement of five LTE-related patents.

Since refocusing the Ottawa-based company on intellectual property licensing in mid-2006, Wi-LAN has signed more than 270 license agreements worth between $725 and $750 million, and has a portfolio of more than 3,000 issued or pending patents.

Quick facts: Wi-LAN Inc

Price: - -

Market: TSX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 1 hour ago

2 min read